OrbiMed’s Gilead Sciences GILD Stock Holding History

OrbiMed’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.31M	Buy	+59,600	New	+$8.35M	0.16%	83
2025 Q2	–	Sell	-197,500	Closed	-$22.1M	–	106
2025 Q1	$22.1M	Sell	197,500 -48,100	-20%	-$4.96M	0.53%	40
2024 Q4	$22.7M	Buy	245,600 +93,900	+62%	+$8.45M	0.47%	48
2024 Q3	$12.7M	Buy	+151,700	New	+$11.6M	0.23%	74
2024 Q1	–	Sell	-100,000	Closed	-$8.1M	–	118
2023 Q4	$8.1M	Hold	100,000	–	–	0.16%	82
2023 Q3	$7.49M	Hold	100,000	–	–	0.16%	91
2023 Q2	$7.71M	Buy	+100,000	New	+$7.98M	0.14%	95
2022 Q3	–	Sell	-287,600	Closed	-$17.8K	–	138
2022 Q2	$17.8K	Hold	287,600	–	–	0.32%	67
2022 Q1	$17.1M	Hold	287,600	–	–	0.28%	73
2021 Q4	$20.9M	Hold	287,600	–	–	0.27%	83
2021 Q3	$20.1M	Hold	287,600	–	–	0.22%	96
2021 Q2	$19.8M	Hold	287,600	–	–	0.2%	100
2021 Q1	$18.6M	Buy	287,600 +95,400	+50%	+$6.15M	0.17%	102
2020 Q4	$11.2M	Hold	192,200	–	–	0.1%	119
2020 Q3	$12.1M	Hold	192,200	–	–	0.15%	104
2020 Q2	$14.8M	Sell	192,200 -1,278,900	-87%	-$98M	0.21%	86
2020 Q1	$110M	Buy	1,471,100 +1,145,000	+351%	+$79.1M	1.85%	15
2019 Q4	$21.2M	Hold	326,100	–	–	0.3%	65
2019 Q3	$20.7M	Sell	326,100 -75,500	-19%	-$4.94M	0.39%	62
2019 Q2	$27.1M	Sell	401,600 -42,200	-10%	-$2.78M	0.42%	57
2019 Q1	$28.9M	Hold	443,800	–	–	0.45%	56
2018 Q4	$27.8M	Buy	443,800 +79,200	+22%	+$5.54M	0.51%	57
2018 Q3	$28.2M	Hold	364,600	–	–	0.34%	77
2018 Q2	$25.8M	Hold	364,600	–	–	0.31%	72
2018 Q1	$27.5M	Sell	364,600 -157,000	-30%	-$12.5M	0.34%	69
2017 Q4	$37.4M	Sell	521,600 -1,406,400	-73%	-$107M	0.47%	61
2017 Q3	$156M	Sell	1,928,000 -145,400	-7%	-$11.1M	1.49%	22
2017 Q2	$147M	Buy	2,073,400 +1,272,500	+159%	+$84.7M	1.54%	21
2017 Q1	$54.4M	Sell	800,900 -254,200	-24%	-$17.9M	0.62%	50
2016 Q4	$75.6M	Sell	1,055,100 -955,600	-48%	-$71M	0.96%	34
2016 Q3	$159M	Sell	2,010,700 -1,062,200	-35%	-$86.3M	1.81%	17
2016 Q2	$256M	Buy	3,072,900 +53,700	+2%	+$4.77M	2.67%	9
2016 Q1	$277M	Sell	3,019,200 -402,200	-12%	-$36.3M	2.92%	9
2015 Q4	$346M	Buy	3,421,400 +1,237,000	+57%	+$129M	3.14%	10
2015 Q3	$214M	Sell	2,184,400 -711,000	-25%	-$79M	2.17%	14
2015 Q2	$339M	Sell	2,895,400 -516,000	-15%	-$56.4M	2.83%	10
2015 Q1	$335M	Sell	3,411,400 -838,100	-20%	-$85.1M	2.86%	6
2014 Q4	$401M	Buy	4,249,500 +487,300	+13%	+$50.4M	3.83%	5
2014 Q3	$400M	Buy	3,762,200 +327,400	+10%	+$32.1M	4.18%	1
2014 Q2	$285M	Sell	3,434,800 -1,880,000	-35%	-$146M	3.34%	5
2014 Q1	$377M	Buy	5,314,800 +322,200	+6%	+$25.3M	4.63%	2
2013 Q4	$375M	Buy	4,992,600 +214,800	+4%	+$15M	5.51%	1
2013 Q3	$300M	Sell	4,777,800 -44,000	-0.9%	-$2.63M	5.36%	1
2013 Q2	$247M	Buy	+4,821,800	New	+$251M	5.24%	2

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

OrbiMed's GILD Position: Q1 2026 in Review

OrbiMed opened a new position in Gilead Sciences (GILD) in Q1 2026: 59,600 shares worth $8.31M. The stake represents 0.16% of the portfolio and ranks #83 among its holdings. This is a return to the name: OrbiMed previously reported a position in GILD as recently as Q1 2025.

OrbiMed first reported a position in GILD in Q2 2013 and has held it in 44 quarters since. The position peaked at $401M in Q4 2014. 2,310 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

OrbiMed held 59,600 shares of Gilead Sciences worth $8.31M as of Q1 2026.
Gilead Sciences was a new OrbiMed position in Q1 2026.
Gilead Sciences made up 0.16% of OrbiMed's portfolio in Q1 2026, its #83 holding.
OrbiMed first reported a position in Gilead Sciences in Q2 2013 and has held it in 44 quarters since.
OrbiMed's Gilead Sciences position peaked at $401M in Q4 2014.
2,310 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.